<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9015</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cancerología]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.cancerol.]]></abbrev-journal-title>
<issn>0123-9015</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cancerología E.S.E.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-90152019000200045</article-id>
<article-id pub-id-type="doi">10.35509/01239015.59</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Actualización de las indicaciones del uso de la radioterapia de intensidad modulada en el Instituto Nacional de Cancerología. Protocolo clínico informado en la evidencia]]></article-title>
<article-title xml:lang="en"><![CDATA[Updating the indications for the use of Intensity-Modulated Radiation Therapy in the Instituto Nacional de Cancerología - Colombia. Clinical protocol reported in the evidence.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ospino]]></surname>
<given-names><![CDATA[Rosalba]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[María Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Feliciano-Alfonso]]></surname>
<given-names><![CDATA[John Edwin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Giovanna Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González]]></surname>
<given-names><![CDATA[Garvin]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ballesteros]]></surname>
<given-names><![CDATA[Holman Duvan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Triviño]]></surname>
<given-names><![CDATA[Paola Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Nacional de Cancerología - ESE Grupo Área Oncología Radioterápica ]]></institution>
<addr-line><![CDATA[Bogotá, D. C. ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Nacional de Cancerología - ESE Grupo de Investigación Clínica ]]></institution>
<addr-line><![CDATA[Bogotá, D. C. ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>23</volume>
<numero>2</numero>
<fpage>45</fpage>
<lpage>55</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-90152019000200045&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-90152019000200045&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-90152019000200045&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes: La radioterapia de intensidad modulada (IMRT) es una técnica avanzada que se usa ampliamente a nivel mundial; sin embargo, su uso adecuado en nuestro país requiere ser revisado.  Objetivo: Actualizar un protocolo clínico (PC) basado en evidencia que contiene las indicaciones clínicas para la utilización de la técnica IMRT en el tratamiento de las patologías oncológicas tratadas más frecuentemente en el servicio de oncología radioterápica del Instituto Nacional de Cancerología (INC) - Colombia.  Métodos: La elaboración de este documento fue realizada por un equipo multidisciplinario empleando un manual nacional para el desarrollo de PC. Se realizó una búsqueda sistemática de la literatura, seguido por la selección de los artículos relevantes y su evaluación utilizando las herramientas apropiadas. La evidencia fue resumida, contextualizada y empleada para generar las recomendaciones mediante un consenso formal tipo RAND/UCLA.  Resultados: Se generaron indicaciones para el uso de la IMRT en pacientes con alguno de los siguientes tipos de cáncer: próstata y pene, cabeza y cuello, piel, sistema nervioso central, mama, sarcomas de tejidos blandos, pulmón, gastrointestinal, ginecológico y urgencias oncológicas.  Conclusiones: En el periodo 2014 a 2017 ha surgido escasa evidencia sobre el impacto de la IMRT en desenlaces relacionados con la supervivencia y la calidad de vida y por tanto el uso de la IMRT sigue siendo en pacientes seleccionados.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Intensity-Modulated Radiation Therapy (IMRT) is an advanced technique which has been put into service in several clinical settings around the world; however, its proper use in Colombia requires to be revisited.  Aim:  To update an evidence-based clinical care protocol (CCP) that contains clinical recommendations for using IMRT in order to treat the most common oncological malignancies seen in the Radiotherapy Unit of the Instituto Nacional de Cancerología - Colombia.  Methods:  The elaboration of this CCP was undertaken by a multidisciplinary team who abided by a domestic CCP-development handbook. Briefly, a systematic search of literature was conducted; afterwards, relevant papers were selected and evaluated using appropriate appraisal tools; finally, evidence was summarized, contextualized, and used for generating the recommendations through a formal consensus approach (RAND/UCLA).  Results:  We established a handful of recommendations for using the IMRT technique in patients with any of the following types of cancer: prostate &amp; penis, head &amp; neck, skin, central nervous system, breast, soft tissue sarcoma, lung, gastrointestinal, and gynecologic, as well as oncologic emergencies.  Conclusions: During the period 2014 - 2017, few evidence has emerged about the impact of IMRT on outcomes related to survival and quality of life; therefore, IMRT use still remains in selected patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Protocolos clínicos]]></kwd>
<kwd lng="es"><![CDATA[Neoplasias]]></kwd>
<kwd lng="es"><![CDATA[Radioterapia de intensidad modulada]]></kwd>
<kwd lng="en"><![CDATA[Clinical Protocols]]></kwd>
<kwd lng="en"><![CDATA[Neoplasms]]></kwd>
<kwd lng="en"><![CDATA[Radiotherapy, Inte39nsity-Modulated]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Cancerología ESE</collab>
<source><![CDATA[Protocolo Indicaciones de IMRT]]></source>
<year>2015</year>
<page-range>1-27</page-range><publisher-loc><![CDATA[Bogotá, Colombia ]]></publisher-loc>
<publisher-name><![CDATA[Manuscrito no publicado]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vallejo-Ortega]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Pedraza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Feliciano-Alfonso]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[García-Pérez]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gutiérrez Sepúlveda]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Merchán-Chaverra]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[Manual Metodológico para la elaboración de protocolos clínicos en el Instituto Nacional de Cancerología]]></source>
<year>2016</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Cancerología]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Kho]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Browman]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Burgers]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Cluz eau]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Feder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[AGREE II: advancing guideline development, reporting and evaluation in health care]]></article-title>
<source><![CDATA[CMAJ]]></source>
<year>2010</year>
<volume>182</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>E839-42</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Gotzsche]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Jüni]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moher]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Oxman]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Cochrane Collaboration's tool for assessing risk of bias in randomised trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2011</year>
<numero>343:d5928</numero>
<issue>343:d5928</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<collab>Scottish Intercollegiate Guidelines Network</collab>
<source><![CDATA[Critical appraisal notes and checklist]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[NICE Guideline on Prostate Cancer: Diagnosis and Management]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Cancer Care Ontario</collab>
<source><![CDATA[CCO Guideline on Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mottet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmunt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bolla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Briers]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cumberbatch]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[De Santis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EAU-ESTRO-SIOG Guidelines on Prostate Cancer]]></article-title>
<source><![CDATA[Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol]]></source>
<year>2017</year>
<volume>71</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>618-29</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Prostate Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Penile Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chien]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[Slezak]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[TN]]></given-names>
</name>
<name>
<surname><![CDATA[Jung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gelfond]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Guía de práctica clínica (GPC) para la detección temprana, diagnóstico, tratamiento, seguimiento y rehabilitación del cáncer de próstata]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veldeman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Madani]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hulstaert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Meerleer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mareel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Neve]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence behind use of intensity-modulated radiotherapy: a systematic review of comparative clinical studies]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2008</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>367-75</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marta]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[de Andrade Carvalho]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[de Arruda]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
<name>
<surname><![CDATA[Hanna]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Gadia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Radiother Oncol]]></source>
<year>2014</year>
<volume>110</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>Cancer Care Ontario</collab>
<source><![CDATA[CCO Guideline on Systemic Therapy in the Curative Treatment of Head and Neck Squamous Cell Cancer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers: Very Advanced Head and Neck Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ratko]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Douglas]]></surname>
<given-names><![CDATA[GW]]></given-names>
</name>
<name>
<surname><![CDATA[de Souza]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Belinson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Aronson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Radiotherapy treatments for head and neck cancer update]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Rockville (USA) ]]></publisher-loc>
<publisher-name><![CDATA[Agency for Healthcare Research and Quality]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Guía de Práctica Clínica con evaluación económica para la prevención, diagnóstico, tratamiento y seguimiento del cáncer de piel no melanoma: carcinoma basocelular]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Guía de Práctica Clínica con evaluación económica para la prevención, diagnóstico, tratamiento y seguimiento del cáncer de piel no melanoma: carcinoma escamocelular de piel]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>Scottish Intercollegiate Guidelines Network (SIGN)</collab>
<source><![CDATA[SIGN Cutaneous melanoma]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>Cancer Care Ontario</collab>
<source><![CDATA[CCO Guideline on The use of adjuvant radiation therapy for curatively resected cutaneous melanoma]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[NICE Guideline on Melanoma: Assessment and Management]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Basal Cell Skin Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>Scottish Intercollegiate Guidelines Network (SIGN)</collab>
<source><![CDATA[SIGN Management of primary cutaneous squamous cell carcinoma]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Cell Skin Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Melanoma]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Dermatofibrosarcoma Protuberans]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Merkel Cell Carcinoma]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cabrera]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fiveash]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Shih]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Koay]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lutz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline]]></article-title>
<source><![CDATA[Pract Radiat Oncol]]></source>
<year>2016</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>217-25</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network.</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Central Nervous System Cancer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Breast Cance]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kouloulias]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Thalassinou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Platoni]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Zygogianni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kouvaris]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Antypas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters]]></article-title>
<source><![CDATA[Biomed Res Int]]></source>
<year>2013</year>
<numero>2013:401261</numero>
<issue>2013:401261</issue>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Neve]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[De Gersem]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Madani]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rational use of intensity-modulated radiation therapy: the importance of clinical outcome]]></article-title>
<source><![CDATA[Semin Radiat Oncol]]></source>
<year>2012</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>40-9</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social.</collab>
<source><![CDATA[Guía de Práctica Clínica (GPC) para la detección temprana, tratamiento integral, seguimiento y rehabilitación de pacientes con cáncer de mama]]></source>
<year>2013</year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>Centro Nacional de Excelencia Tecnológica en Salud</collab>
<source><![CDATA[Guía para el diagnóstico y tratamiento del sarcoma de tejidos blandos en extremidades yretroperitoneo en adultos]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Soft Tissue Sarcoma]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<collab>The Royal College of Radiologist</collab>
<source><![CDATA[Radiotherapy Dose Fractionation]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roeder]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ulrich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Habl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Uhl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Saleh-Ebrahimi]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: interim analysis]]></article-title>
<source><![CDATA[BMC Cancer.]]></source>
<year>2014</year>
<numero>14</numero>
<issue>14</issue>
<page-range>617</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Folkert]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Brennan]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Kuk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>29</numero>
<issue>29</issue>
<page-range>3236-41</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia -Instituto Nacional de Cancerología</collab>
<source><![CDATA[Guía de Práctica Clínica para la detección temprana, diagnóstico, estadificación, y tratamiento del cáncer de pulmón]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<source><![CDATA[SIGN Management of lung cancer]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="">
<collab>American Society for Radiation Oncology</collab>
<source><![CDATA[Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline]]></source>
<year>2015</year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Small Cell Lung Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is IMRT superior or inferior to 3DCRT in radiotherapy for NSCLC? A meta-analysis]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2016</year>
<volume>11</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Choy]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Komaki]]></surname>
<given-names><![CDATA[RU]]></given-names>
</name>
<name>
<surname><![CDATA[Timmerman]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Schild]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2017</year>
<volume>35</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>56-62</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[NICE Guideline on Colorectal cancer: Diagnosis and Management]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="">
<collab>Scottish Intercollegiate Guidelines Network (SIGN)</collab>
<source><![CDATA[SIGN Diagnosis and management of colorectal cancer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Esophageal and Esophagogastric Junction Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Gastric Cancer]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="">
<collab>European Society for Medical Oncology</collab>
<source><![CDATA[ESMO Guideline on Gastric cancer: ESMO Clinical Practice Guidelines for Diagnosis, treatment and Follow-up]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Hepatobiliary Cancers]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Patton]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffe]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Haddock]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Appropriate customization of radiation therapy for stage II and III rectal cancer: Executive summary of an ASTRO Clinical Practice Statement using the RAND/UCLA Appropriateness Method]]></article-title>
<source><![CDATA[Pract Radiat Oncol]]></source>
<year>2016</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>166-75</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Colon Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Rectal Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Anal Carcinoma]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="">
<collab>Cancer Care Ontario</collab>
<source><![CDATA[CCO Guideline on The Role of IMRT in Gastrointestinal Cancers]]></source>
<year>2010</year>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="">
<collab>Ministerio de Salud y Protección Social de Colombia</collab>
<source><![CDATA[Guía de práctica clínica para el manejo del cáncer de cuello uterino invasivo]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Cervical Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="">
<collab>American Society for Radiation Oncology</collab>
<source><![CDATA[ASTRO Guideline on the Role of Postoperative Radiation Therapy for Endometrial Cancer]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Beriwal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Beyer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jhingran]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An Analysis of Appropriate Delivery of Postoperative Radiation Therapy for Endometrial Cancer Using the RAND/ UCLA Appropriateness Method: Executive summary]]></article-title>
<source><![CDATA[Adv Radiat Oncol]]></source>
<year>2015</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>26-34</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="">
<collab>National Comprehensive Cancer Network</collab>
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology Vulvar Cancer]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="">
<collab>Alberta Health Services</collab>
<source><![CDATA[Oncologic Emergencies: A Guide for Family Physicians]]></source>
<year>2014</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
